BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ramai D, Tai W, Rivera M, Facciorusso A, Tartaglia N, Pacilli M, Ambrosi A, Cotsoglou C, Sacco R. Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma. Biomedicines 2021;9:184. [PMID: 33673113 DOI: 10.3390/biomedicines9020184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hagiwara S, Nishida N, Ueshima K, Minami Y, Komeda Y, Aoki T, Takita M, Morita M, Chishina H, Yoshida A, Ida H, Kudo M. Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. Cells 2021;10:3257. [PMID: 34831479 DOI: 10.3390/cells10113257] [Reference Citation Analysis]
2 Lee HW, Lee IJ, Lee SJ, Kim YR, Kim HM. Highly Sensitive Two-Photon Lipid Droplet Tracker for In Vivo Screening of Drug Induced Liver Injury. ACS Sens 2022;7:1027-35. [PMID: 35385270 DOI: 10.1021/acssensors.1c02679] [Reference Citation Analysis]
3 Wang T, Hu L, Lu J, Xiao M, Liu J, Xia H, Lu H. Functional metabolomics revealed functional metabolic-characteristics of chronic hepatitis that is significantly differentiated from acute hepatitis in mice. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106248] [Reference Citation Analysis]
4 Ghidini M, Ramai D, Facciorusso A, Singh J, Tai W, Rijavec E, Galassi B, Grossi F, Indini A. Metabolic disorders and the risk of cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:999-1007. [PMID: 34423721 DOI: 10.1080/17474124.2021.1946393] [Reference Citation Analysis]
5 Kudo M. Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma? Liver Cancer 2021;10:289-95. [PMID: 34414117 DOI: 10.1159/000517841] [Reference Citation Analysis]
6 Baumgartner S, Shiri-Sverdlov R. NASH and Systemic Complications: From Basic to Clinical Research. Biomedicines 2021;9:1913. [PMID: 34944726 DOI: 10.3390/biomedicines9121913] [Reference Citation Analysis]
7 Ramai D, Facciorusso A, Vigandt E, Schaf B, Saadedeen W, Chauhan A, di Nunzio S, Shah A, Giacomelli L, Sacco R. Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Cells 2021;10:3401. [PMID: 34943908 DOI: 10.3390/cells10123401] [Reference Citation Analysis]
8 Zhang Z, Li D, Cao Y, Wang Y, Wang F, Zhang F, Zheng S. Biodegradable Hypocrellin B nanoparticles coated with neutrophil membranes for hepatocellular carcinoma photodynamics therapy effectively via JUNB/ROS signaling. Int Immunopharmacol 2021;99:107624. [PMID: 34343939 DOI: 10.1016/j.intimp.2021.107624] [Reference Citation Analysis]